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Abstract
Background: The prevalence and role of Chlamydia pneumoniae in chronic obstructive pulmonary
disease (COPD) remain unclear.
Methods: Peripheral blood mononuclear cells were obtained from 100 outpatients with smoking-
related, clinically stable COPD, and induced sputum was obtained in 62 patients.
Results: Patients had mean age (standard deviation) of 65.8 (10.7) years, mean forced expiratory
volume in one second of 1.34 (0.61) L, and 61 (61.0%) were male. C. pneumoniae nucleic acids were
detected by nested polymerase chain reaction in 27 (27.0%). Current smoking (odds ratio {OR} =
2.6, 95% confidence interval {CI}: 1.1, 6.6, P = 0.04), season (November to April) (OR = 3.6, 95%
CI: 1.4, 9.2, P = 0.007), and chronic sputum production (OR = 6.4, 95% CI: 1.8, 23.2, P = 0.005)
were associated with detection of C. pneumoniae DNA.
Conclusions: Prospective studies are needed to examine the role of C. pneumoniae nucleic acid
detection in COPD disease symptoms and progression.
Background
Chronic obstructive pulmonary disease (COPD) is a ma-
jor cause of morbidity and mortality throughout the
world [1]. By 2020, the World Health Organization pre-
dicts that COPD will become the 5th (currently 12th) most
prevalent disease worldwide, and the 3rd (currently 6th)
most common cause of death [2]. Smoking is the major
identified risk factor, and approximately 15% of smokers
develop COPD [1]. Smoking cessation reduces the rate of
decline in forced expiratory volumes, but no pharmaco-
logical intervention has been shown to modify the pro-
gression of disease. Bacterial and viral infections of the
respiratory tract trigger acute exacerbations of chronic
bronchitis, and may contribute to disease progression [3].
A role for Chlamydia pneumoniae in patients with COPD
remains unclear. C. pneumoniae infection, diagnosed sero-
logically, caused 5 to 10% of acute exacerbations in pa-
tients with chronic bronchitis [4,5]. The seroprevalence
and geometric mean titres of C. pneumoniae IgG [5,6]. and
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IgA [7] antibodies were higher in COPD patients than
controls, irrespective of exacerbation status. Von Hertzen
et al measured serum IgG and IgA, salivary secretory IgA,
circulating immune complexes, and nucleic acid, and
found evidence of "chronic" C. pneumoniae infection in
65% of COPD patients [8], and recently Lieberman et al
showed an association between C. pneumoniae serology,
determined by a commercial immunoassay, and COPD
exacerbation [9]. However, the reproducibility and validi-
ty of serologic testing remain uncertain [10].
Given these limitations of serology, the direct detection of
C. pneumoniae nucleic acids may facilitate studies of its
role in chronic disease etiology. The presence of C. pneu-
moniae has been directly demonstrated in lung tissue [11],
and correlated with detection of C. pneumoniae DNA in
peripheral blood mononuclear cells (PBMC) by PCR (Bla-
si et al, Proceedings of the Fourth Meeting of the European
Society for Chlamydia Research, Helsinki, Finland, 2000).
However, there are limited data regarding the prevalence
of C. pneumoniae DNA in PBMC of COPD patients.
In a previous study, we found that PBMC C. pneumoniae
DNA detection among cardiac patients [12] was associat-
ed with current smoking and winter/spring season. The
primary objective of this study was to examine the preva-
lence and clinical determinants of C. pneumoniae DNA in
COPD patients, and in particular to validate the observed
association with current smoking and season. Secondary
objectives were to explore whether C. pneumoniae detec-
tion was associated with unique symptoms, pulmonary
function, or sputum cell counts, and to contrast the prev-
alence among respirology and cardiology patients.
Materials and methods
Subjects
One hundred consecutive consenting outpatients were re-
cruited from the Firestone Institute for Respiratory Health
at St. Joseph's Healthcare between March 2000 and Octo-
ber 2001. The study protocol was approved by the hospi-
tal's Research Ethics Board, and all subjects gave written
consent. Patient characteristics are summarized in Table 1.
Patients were current or former smokers who had a previ-
ous diagnosis of smoking-related chronic airflow limita-
tion, with best forced expiratory volume in one second
(FEV1) of < 70% predicted and FEV1/Vital Capacity <
70%, were clinically stable, and had not received antibiot-
ics in the prior month. Spirometry was obtained before
and 10 minutes after inhalation of 200 µg inhaled salb-
utamol. Detailed smoking history, symptoms, use of cor-
ticosteroids, and past history of pneumonia, diabetes
mellitus, angina pectoris, and myocardial infarction were
obtained. Clinical and laboratory data were collected in-
dependently by blinded study personnel. Seven patients
with no history of prior smoking were enrolled, and their
spirometry data and sputum cell counts were excluded
from the analyses.
Sample size
A sample size of 100 produces a 95% confidence interval
equal to the sample proportion ± 0.08 when the estimated
proportion is 0.20. For an estimated 50% prevalence of
each of current smoking and season, assuming independ-
ence, the study had 64% power to detect an odds ratio
(OR) of 5.0 or higher, and 40% power to detect an odds
ratio of 3.0 or higher, for each of these factors as predictors
of C. pneumonia DNA detection, using X2 test with conti-
nuity correction and with a significance level of 0.05, two-
tailed (Power Analysis and Sample Size for Windows
2000, NCSS, Kaysville, UT, USA).
Sputum induction and examination
Sputum induction and processing was performed as de-
scribed by Pizzichini et al [13] for the first 73 patients, and
no sputum was collected for remaining patients. Sputum
induction was discontinued based on low prevalence of
C. pneumoniae DNA and to increase enrollment. A differ-
ential count of 400 non-squamous cells was performed by
experienced laboratory technologists, and a sample of
sputum was frozen at -70°C for PCR testing in 62 patients.
Insufficient sputum was available on the remaining 11 pa-
tients after performance of sputum cytology.
Blood collection
Peripheral blood mononuclear cells (PBMC) were ob-
tained by venipuncture into an 8 mL cell preparation tube
(CPT, BD Vacutainer Systems, Franklin Lakes, NJ, USA).
Within 2 hours of venipuncture, specimens were mixed by
inversion and centrifuged at 1500 ×  g for 30 minutes. The
mononuclear cells layer was aspirated and frozen at -
70°C. Samples were thawed in batches, 200–500 µL aliq-
uots were pelleted and extracted using QIAamp DNA
mini-kits (Qiagen, Mississauga ON) into 50–100 µL of
elution buffer.
Detection of chlamydia pneumoniae DNA
A 5–10 µL aliquot was amplified in triplicate by a nested
polymerase chain reaction (PCR) targeting the ompA gene
[14], consisting of 40 amplification cycles for a 333 base
pair product and 30 cycles for a 207 bp product, followed
by separation on a 2.0% (weight/volume) TAE agarose gel
containing ethidium bromide, with ultraviolet light visu-
alization. The 207 base pair product was confirmed as C.
pneumoniae by hybridization with a specific fluorescein-la-
beled oligonucleotide probe (ECL, Amersham). A probe-
confirmed positive in any of the three reactions was con-
sidered a positive, as previously described [12,15]. Eight
controls, consisting of one low strength positive control
and one intermediate strength positive control, six nega-
tive controls without DNA, and one additional tube withBMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/12
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master mix open to the air throughout specimen addition,
were run for every 13 patient specimens. PCR extraction
and amplification were performed in separate rooms.
Nicotine metabolites assay
Using the plasma fraction from the citrated CPT tube, nic-
otine metabolites were assayed in 73 patients by enzyme
immunoassay (Immulite Nicotine Metabolite detection
kit, Diagnostic Products Corporation, Los Angeles CA,
USA). The Immulite nicotine metabolite assay has a cali-
bration range of 10 to 500 µg/L, and non-smokers are de-
fined by a nicotine metabolite level of < 25 µg/mL.
Statistical analysis
Continuous variables were tested by unpaired t-test or
Mann Whitney U test, and proportions were compared us-
ing X2 or Fisher exact tests (unmatched data) or the McNe-
mar test (matched data). Multiple logistic regression
modeling (SPSS for Windows 10.0, SPSS Inc., Chicago IL)
was undertaken using DNA status (in blood or sputum) as
the response variable. A priori, an association with current
smoking and with winter/spring season was expected. All
associations with clinical history, spirometry and cell
counts were considered hypothesis-generating. To exam-
ine the effect of missing data, smoking and season were
analyzed after imputation of C. pneumoniae DNA status
for PBMC negative subjects in whom sputum data was
missing. Imputation was performed based on proportion
sputum DNA positive among subjects who were DNA
negative in PBMC (SPSS).
Prevalence of PBMC C. pneumoniae DNA in COPD pa-
tients was compared with our coronary angiography
study[12] using gender, smoking and season-stratified
Maentel-Haentzel X2. Predictors of FEV1 were modeled by
linear regression, for the entire study group and separately
by age ≤  65 years or >65 years. A P-value of < 0.05, two-
tailed, was considered statistically significant for the pri-
mary hypothesis of an association with current smoking
or season, and a P-value of < 0.01, two-tailed, was consid-
ered significant for all secondary analyses.
Results
C. pneumoniae DNA prevalence was 24 of 100 (24.0%) in
PBMC and 7 of 62 (11.3%) in induced sputum, for a total
of 27 of 100 (27.0%) patients positive in at least one spec-
imen type. Among 62 subjects from whom both PBMC
and sputum were obtained, PBMC detected 21 of 24
(87.5%) positives, whereas sputum detected 7 of 24
(29.2%) positives (P = 0.003, McNemar test).
C. pneumoniae DNA detection in PBMC or sputum by cat-
egorical clinical characteristics is tabulated in Table 1,
with unadjusted odds ratios, and by continuous clinical
and laboratory characteristics in Table 2.
Current smoking (OR = 3.5, 95% CI: 1.2, 9.9, P = 0.02)
and season (November to April, OR = 3.9, 95% CI: 1.4,
10.9, P = 0.008) were associated with DNA detection, in-
dependent of age and gender, whereas male gender was
not (OR = 2.2, 95% CI: 0.8, 6.3, P = 0.14). A month-by-
month breakdown for C. pneumoniae DNA positive PBMC
is illustrated in Figure 1. The composite of current smok-
ing or season identified 25 of 27 (92.6%) C. pneumoniae
positives, and was strongly associated with DNA detection
(age and gender adjusted OR = 11.1, 95% CI: 2.4, 50.5, P
= 0.002). The composite of smoking or season was also as-
sociated with DNA detection in PBMC alone (adjusted OR
= 9.0, 95% CI: 2.0, 41.4, P = 0.005).
Table 1: Patient characteristics by Chlamydia pneumoniae DNA detection status.
Entire Study Group (%) DNAa Present (%) DNA Absent (%) Unadjusted ORb (95% CI)
Number 100 27 (27.0) 73 (73.0)
Male 61 / 100 (61.0) 20 / 27 (74.1) 41 / 73 (56.2) 2.2 (0.8, 5.9)
Current smoking 32 / 100 (32.0) 13 / 27 (48.1) 19 / 73 (26.0) 2.6 (1.1, 6.6)
Season (Nov. to April) 44 / 100 (44.0) 18 / 27 (66.7) 26 / 73 (35.6) 3.6 (1.4, 9.2)
Smoker or Season 63 / 100 (63.0) 25 / 27 (92.6) 38 / 73 (52.1) 11.5 (2.5, 52.2)
Chronic cough 50 / 98 (51.0) 16 / 26 (61.5) 34 / 72 (47.2) 1.8 (0.7, 4.5)
Chronic sputum 64 / 99 (64.6) 24 / 27 (88.9) 40 / 72 (55.6) 6.4 (1.8, 23.2)
Pneumonia in 1 year 9 / 98 (9.2) 2 / 26 (7.7) 7 / 72 (9.7) 0.8 (0.2, 4.0)
Prednisone 18 / 98 (18.4) 3 / 27 (11.1) 15 / 71 (21.1) 0.5 (0.1, 1.8)
Inhaled corticosteroids 67 / 98 (68.4) 19 / 27 (70.4) 48 / 71 (67.6) 1.1 (0.4, 3.0)
Coronary artery disease 10 / 92 (10.9) 2 / 27 (7.4) 8 / 65 (12.3) 0.6 (0.1, 2.9)
Diabetes mellitus 5 / 92 (5.4) 2 / 27 (7.4) 3 / 65 (4.6) 1.7 (0.3, 10.5)
aC. pneumoniae DNA detected by nested polymerase chain reaction [14]. b Unadjusted odds ratios (OR) with 95% confidence intervals (SPSS).BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/12
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To further explore the relationship between current smok-
ing status and the detection of C. pneumoniae DNA, we
measured plasma nicotine metabolites in 73 subjects. Lev-
els = 25 µg/L indicate current smoking status. At this
threshold, seven former smokers were reclassified as cur-
rent smokers, and one current smoker as a former smoker.
Nicotine metabolites = 25 µg/L were associated with C.
pneumoniae DNA with OR of 2.1 (95% CI: 0.8, 5.7, P =
0.13). There was no relationship between higher plasma
nicotine levels and the probability of detecting Chlamydia
pneumoniae DNA (see Figure 2.)
To assess the influence of missing C. pneumoniae DNA sta-
tus of sputum, imputation of one, three or seven addition-
al sputum positives was performed, corresponding to the
proportion of observed sputum DNA positives with 95%
confidence interval among subjects who were PBMC DNA
negative. Imputation was performed without regard to
smoking or season. The OR associated with season was
3.7 in the non-imputed model, and 3.4, 3.1, and 2.4 re-
spectively for one, three or seven imputed positives, in a
model adjusted for smoking, age and gender. The ORs for
smoking in these models were 3.7, 3.4, 2.6, and 2.0, for
the zero, one, three or seven imputed positives, respective-
ly.
Self-reported chronic sputum production was associated
with C. pneumoniae DNA detection (age, gender, smoking
and season-adjusted OR = 4.2, 95% CI: 1.1, 16.0, P =
0.04), whereas self-reported chronic cough, use of corti-
costeroids, or a history of coronary artery disease or diabe-
tes mellitus were not (see Table 1). Chronic sputum
production identified 24 of 27 (88.9%) of patients with C.
pneumoniae DNA detected. In a forward selection model
including sputum production, smoking, season, gender
and age, only sputum production (OR = 5.3, 95% CI: 1.4,
19.6, P = 0.01) and season (OR = 2.8, 95% CI: 1.1, 7.5, P
= 0.04) were independent predictors. Two-way interac-
tions were not statistically significant.
We examined the association between C. pneumoniae
DNA and measures of pulmonary function (Table 2), and
sputum cell counts. Pulmonary function was moderately
to severely impaired, and no relationship was found with
C. pneumoniae DNA detection. Sputum neutrophil, mac-
rophage, and eosinophil counts were not associated with
C. pneumoniae detection.
We also examined the association between C. pneumoniae
DNA and spirometry by linear regression modeling of
FEV1. Age, gender, current smoking, C. pneumoniae DNA
status, and season were included in the model (Table 3).
In the entire study group, age and male gender were pre-
dictors of FEV1. However, if we used the per cent predicted
FEV1 as the outcome variable, no variable was significant
at the P < 0.05 level (data not shown), and only smoking
approached this level of significance (P = 0.09). We then
examined subjects aged 65 years or younger, and those
older than 65 years, separately. In the younger age group,
age predicted FEV1, whereas current smoking, male gen-
der and C. pneumoniae DNA status were associated at P <
0.10. In the older age group, male gender was associated
with FEV1, but age, current smoking, season or DNA sta-
tus were not.
PBMC results from the COPD patients in this study were
compared with patients from the coronary angiography
study reported previously [12]. COPD patients were more
Table 2: Spirometrya and sputum cell counts by Chlamydia pneumoniae DNA detection status among 92 patients with chronic obstruc-
tive pulmonary disease.
Number of Subjects Entire Study Group DNAb Present DNA Absent P-value (t-test)
Age in years (SD) 93 65.8 (10.7) 66.9 (11.9) 65.3 (10.3) 0.53
Smoking pack-years (SD) 93 43.1 (25.1) 48.9 (29.3) 41.8 (24.1) 0.22
FEV1
c (SD), L 93 1.35 (0.61) 1.34 (0.64) 1.36 (0.61) 0.88
FEV1 % predicted (SD) 93 46.9 (16.8) 44.3 (15.1) 48.0 (17.5) 0.33
FEV1/VCd % (SD) 93 45.7 (15.4) 42.6 (15.8) 47.0 (15.2) 0.22
Total cell count, 106/g (SD) 73 10.9 (15.4) 9.9 (12.5) 11.4 (16.8) 0.70
Viability, % (SD) 73 61.5 (24.2) 60.4 (22.7) 62.0 (25.0) 0.79
Squamous Epithelial, % (SD) 73 3.8 (8.6) 3.7 (5.3) 3.9 (10.0) 0.92
Neutrophils, % (SD) 73 63.6 (25.3) 60.6 (27.2) 65.2 (24.5) 0.46
Macrophages, % (SD) 73 25.6 (19.2) 26.4 (21.2) 25.2 (18.3) 0.78
Eosinophils, median % (Inter-quartile range)e 73 1.2 (3.0) 1.2 (3.7) 1.0 (2.9) 0.71e
aAll spirometry after inhalation of 200 µg salbutamol. bC. pneumoniae DNA detected in peripheral blood mononuclear cells or induced sputum by 
nested polymerase chain reaction [14]. cFEV1: forced expiratory volume in 1 second. dVC: vital capacity. eComparison by Mann Whitney U test 
(SPSS).BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/12
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likely to have C. pneumoniae DNA in PBMC than patients
undergoing coronary angiography (24 of 100 versus 24 of
208, adjusted OR = 2.9, 95% CI: 2.4, 9.9, P < 0.001), in-
dependent of current smoking status, gender, or season.
The highest monthly prevalence was found in March and
April, irrespective of year or study group. Among cardiol-
ogy patients, the C. pneumoniae prevalence in March and
April 1999 was 16% (20 of 122), compared with a preva-
lence of 5% (3 of 60) in the months of May to October.
Similarly, in COPD patients studied in 2000 and 2001,
March and April prevalence was 50% (9 of 18), compared
with 15% (6 of 41) in the months of May to October. In
the combined dataset, season (November to April OR =
4.3, 95% CI: 2.0, 9.2, P < 0.001) and smoking (OR = 2.7,
95% CI: 1.3, 5.4, P = 0.005) predicted C. pneumoniae DNA
detection in PBMC, whereas male gender did not (OR =
1.5, 95% CI: 0.7, 3.2, P = 0.28). The combined measure of
current smoking or season was associated with DNA de-
tection (OR = 10.1, 95% CI: 3.0, 33.8, P < 0.001).
Discussion
Among clinically stable patients with smoking-related
COPD and moderate to severe pulmonary function im-
pairment, we detected a relatively high prevalence of C.
pneumoniae DNA. Peripheral blood (PBMC) specimens
were superior to induced sputa, and an association be-
tween C. pneumoniae DNA detection, current smoking and
winter/spring months was demonstrated. Chronic spu-
tum production was associated with C. pneumoniae, but
we found no clear association with other clinical symp-
toms, measures of lung function, or sputum cell counts.
Data on the prevalence of C. pneumoniae DNA in PMBC of
COPD patients have been published solely in abstract
form. Black et al found a prevalence of 14 of 20 (70.0%,
95% CI: 48.1, 85.5) Australian patients, using whole
blood or PBMC (Black et al, Proceedings of the Fourth
Meeting of the European Society for Chlamydia Research,
Helsinki, Finland, 2000). Blasi et al found a prevalence of
10 among 21 (47.6%, 95% CI: 28.3, 67.6) Italian pa-
tients, compared with 11 of 21 (52.4%) who had C. pneu-
moniae DNA in trans-bronchial lung biopsy specimens
(Blasi et al, Proceedings of the Fourth Meeting of the Eu-
ropean Society for Chlamydia Research, Helsinki, Fin-
land, 2000). Our prevalence of 24.0% in PBMC of
Canadian COPD patients is slightly lower than these pre-
vious estimates, although within the 95% confidence in-
terval for Blasi et al's estimate. Although this estimate was
higher for patients with chronic respiratory disease com-
pared with patients undergoing coronary angiography, we
have recently found a high prevalence (31/103, 29.8%)
among family practice controls without acute cardiorespi-
ratory symptoms (Smieja et al, unpublished data).
We found a low prevalence (11%) of C. pneumoniae DNA
in induced sputum among patients with chronic stable
COPD. By contrast, Von Hertzen et al detected DNA in
spontaneous sputum of 59% of patients with severe
COPD [8], and Black et al detected DNA in 94% of pa-
tients hospitalized for COPD exacerbation (Black et al,
Proceedings of the Fourth Meeting of the European Socie-
ty for Chlamydia Research, Helsinki, Finland, 2000). We
obtained induced sputum to measure sputum cell counts
by a validated methodology, but spontaneous sputum
Figure 1
Relation of Chlamydia pneumoniae (CP) DNA prevalence in
blood peripheral mononuclear cells versus month of study
visit among 100 patients presenting to a respirology referral
clinic. CP-DNA positive (solid), CP-DNA negative (thatched)
or proportion of all monthly specimens which were CP-
DNA positive (line).
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Figure 2
Relation of Chlamydia pneumoniae DNA prevalence in blood
or sputum versus plasma nicotine metabolite levels among 73
patients with stable chronic obstructive pulmonary disease.
Nicotine metabolites of < 25 µg/L indicate no recent expo-
sure to smoking. For nicotine metabolites = 25 µg/L, odds
ratio = 2.1 (95% CI: 0.8, 5.7, P = 0.13) for detection of C.
pneumoniae DNA (SPSS).
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may be superior for routine C. pneumoniae detection. Con-
versely, sputum positivity may be higher during acute ex-
acerbations, and our study intentionally excluded such
patients. Our data support the utility of PBMC in prefer-
ence to sputum for C. pneumoniae DNA detection.
A clearer relationship between C. pneumoniae and smok-
ing is emerging. Hahn first proposed that smoking was a
potential confounder of the association between C. pneu-
moniae antibody levels and cardiovascular disease [16].
Von Hertzen et al showed that smoking was associated
with higher C. pneumoniae IgA levels in smoking-discord-
ant twins [17], and Karvonen et al showed that C. pneumo-
niae IgG seropositivity to be higher in smokers in a
population-based study [18]. This study has validated our
previous observation that current smoking was associated
with a higher prevalence of C. pneumoniae nucleic acid de-
tection [12]. Whether C. pneumoniae associations with
chronic diseases such as COPD or coronary artery disease
are confounded by inaccurate ascertainment of smoking
status, or whether infection is directly involved in the
causal pathway for smoking-associated diseases, will re-
quire careful investigation.
Annual C. pneumoniae seasonal cycles have not, to our
knowledge, been previously reported. Among both cardi-
ology and respirology patients, we found peak prevalence
in the winter/spring months, particularly in March and
April, over three consecutive winters. Whether similar sea-
sonal variation is present in other geographic areas is not
known.
We identified no clear relationship between FEV1 and C.
pneumoniae DNA detection. In the sub-group of patients
aged 65 years or younger, current smoking and C. pneumo-
niae DNA status were each associated with a reduced of
FEV1 approximately 400 mL, although neither was nomi-
nally significant at a level of P < 0.05. A larger sample size
may allow more precise estimation of this relationship, al-
though only a prospective study design will adequately
determine whether DNA detection is associated with
greater decline in FEV1. Our data suggest that a study en-
rolling subjects 65 years or younger may have greater pow-
er for examining whether C. pneumoniae is associated with
lung function decline independently of smoking status.
We identified self-reported chronic sputum production as
a strong risk factor for C. pneumoniae DNA detection.
However, this association requires validation, and was not
significant at P < 0.01 as we pre-specified for secondary
analyses. Nevertheless, C. pneumoniae DNA detection in
stable COPD patients may be associated with respiratory
symptoms.
In conclusion, C. pneumoniae was prevalent in patients
with COPD and associated with current smoking and win-
ter/spring season, and may be associated with chronic
sputum production. C. pneumoniae DNA detection in
PBMC may facilitate the undertaking of large prospective
epidemiologic studies examining the role of C. pneumoni-
ae in COPD etiology and progression.
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